v3.26.1
Segments
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segments Segments
An operating segment is identified as a component of an enterprise about which separate discrete financial information is available for evaluation by the Chief Operating Decision Maker ("CODM") in making decisions, including regarding resource allocation and assessing performance. The Company’s Chief Executive Officer is its CODM.

The Company's CODM uses consolidated single-segment (one) financial information for purposes of: allocating resources, evaluating performance, making operating decisions, setting incentive targets, and planning and forecasting for future periods. The Company's CODM makes such decisions based on consolidated net loss. This measure is used to monitor budget versus actual results to evaluate the performance of the segment. Managing and allocating resources on a consolidated basis enables the CODM to assess the overall level of resources available and how to deploy these resources across functions and operations (including research and development) that align with the Company’s strategic goals. All of the Company’s long-lived assets are held in the United States.

The following table is representative of the significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment.


Three Months Ended March 31,
20262025
Program expenses(1)
Atebimetinib (IMM-1-104)$4,055,258 $4,257,936 
Envometinib (IMM-6-415)4,345 1,623,755 
Other programs2,019,865 1,242,109 
Non-program expenses(2)
1,469,553 1,204,385 
Employee-related costs6,067,936 5,378,938 
Stock-based compensation expense1,636,675 1,692,267 
Depreciation and amortization81,402 85,261 
Other segment items(3)
(1,874,139)(438,519)
Net loss$13,460,895 $15,046,132 

(1) Includes direct research and development expenses.
(2) Includes general and administrative expenses, in addition to facilities and other research and development expenses.
(3) Includes interest income and other (income) expense.